Defining and using immune archetypes to classify and treat cancer

Alexis J Combes^{1

2

3

4

5}, Bushra Samad^{6

7

8

9}, Matthew F Krummel^{10

11

12}

Affiliations

¹ Department of Pathology, University of California San Francisco, San Francisco, CA, USA. alexis.combes@ucsf.edu.
² Bakar ImmunoX Initiative, University of California San Francisco, San Francisco, CA, USA. alexis.combes@ucsf.edu.
³ UCSF Immunoprofiler Initiative, University of California San Francisco, San Francisco, CA, USA. alexis.combes@ucsf.edu.
⁴ UCSF CoLabs, University of California San Francisco, San Francisco, CA, USA. alexis.combes@ucsf.edu.
⁵ Department of Medicine, University of California San Francisco, San Francisco, CA, USA. alexis.combes@ucsf.edu.
⁶ Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
⁷ Bakar ImmunoX Initiative, University of California San Francisco, San Francisco, CA, USA.
⁸ UCSF Immunoprofiler Initiative, University of California San Francisco, San Francisco, CA, USA.
⁹ UCSF CoLabs, University of California San Francisco, San Francisco, CA, USA.
¹⁰ Department of Pathology, University of California San Francisco, San Francisco, CA, USA. matthew.krummel@ucsf.edu.
¹¹ Bakar ImmunoX Initiative, University of California San Francisco, San Francisco, CA, USA. matthew.krummel@ucsf.edu.
¹² UCSF Immunoprofiler Initiative, University of California San Francisco, San Francisco, CA, USA. matthew.krummel@ucsf.edu.

PMID: 37277485
DOI: 10.1038/s41568-023-00578-2

Review

Defining and using immune archetypes to classify and treat cancer

Alexis J Combes et al. Nat Rev Cancer. 2023 Jul.

. 2023 Jul;23(7):491-505.

doi: 10.1038/s41568-023-00578-2. Epub 2023 Jun 5.

Authors

Alexis J Combes^{1

2

3

4

5}, Bushra Samad^{6

7

8

9}, Matthew F Krummel^{10

11

12}

Affiliations

¹ Department of Pathology, University of California San Francisco, San Francisco, CA, USA. alexis.combes@ucsf.edu.
² Bakar ImmunoX Initiative, University of California San Francisco, San Francisco, CA, USA. alexis.combes@ucsf.edu.
³ UCSF Immunoprofiler Initiative, University of California San Francisco, San Francisco, CA, USA. alexis.combes@ucsf.edu.
⁴ UCSF CoLabs, University of California San Francisco, San Francisco, CA, USA. alexis.combes@ucsf.edu.
⁵ Department of Medicine, University of California San Francisco, San Francisco, CA, USA. alexis.combes@ucsf.edu.
⁶ Department of Pathology, University of California San Francisco, San Francisco, CA, USA.
⁷ Bakar ImmunoX Initiative, University of California San Francisco, San Francisco, CA, USA.
⁸ UCSF Immunoprofiler Initiative, University of California San Francisco, San Francisco, CA, USA.
⁹ UCSF CoLabs, University of California San Francisco, San Francisco, CA, USA.
¹⁰ Department of Pathology, University of California San Francisco, San Francisco, CA, USA. matthew.krummel@ucsf.edu.
¹¹ Bakar ImmunoX Initiative, University of California San Francisco, San Francisco, CA, USA. matthew.krummel@ucsf.edu.
¹² UCSF Immunoprofiler Initiative, University of California San Francisco, San Francisco, CA, USA. matthew.krummel@ucsf.edu.

PMID: 37277485
DOI: 10.1038/s41568-023-00578-2

Abstract

Tumours are surrounded by a host immune system that can suppress or promote tumour growth. The tumour microenvironment (TME) has often been framed as a singular entity, suggesting a single type of immune state that is defective and in need of therapeutic intervention. By contrast, the past few years have highlighted a plurality of immune states that can surround tumours. In this Perspective, we suggest that different TMEs have 'archetypal' qualities across all cancers - characteristic and repeating collections of cells and gene-expression profiles at the level of the bulk tumour. We discuss many studies that together support a view that tumours typically draw from a finite number (around 12) of 'dominant' immune archetypes. In considering the likely evolutionary origin and roles of these archetypes, their associated TMEs can be predicted to have specific vulnerabilities that can be leveraged as targets for cancer treatment with expected and addressable adverse effects for patients.

PubMed Disclaimer

References

1. Silverstein, A. M. The curious case of the 1960 Nobel Prize to Burnet and Medawar. Immunology 147, 269–274 (2016). - PubMed - PMC - DOI
1. Krummel, M. F., Sullivan, T. J. & Allison, J. P. Superantigen responses and costimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int. Immunol. 8, 101–105 (1996). - DOI
1. Kearney, E. R. et al. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4⁺ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155, 1032–1036 (1995). - PubMed - DOI
1. Salama, A. D. et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198, 71–78 (2003). - PubMed - PMC - DOI
1. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015). - PubMed - PMC - DOI

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Defining and using immune archetypes to classify and treat cancer

Affiliations

Defining and using immune archetypes to classify and treat cancer

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous